163 related articles for article (PubMed ID: 9111301)
21. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
22. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
[TBL] [Abstract][Full Text] [Related]
23. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
24. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
27. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
28. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
[TBL] [Abstract][Full Text] [Related]
29. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
Guise CP; Grove JI; Hyde EI; Searle PF
Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
[TBL] [Abstract][Full Text] [Related]
30. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
[TBL] [Abstract][Full Text] [Related]
31. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
McNeish IA; Green NK; Gilligan MG; Ford MJ; Mautner V; Young LS; Kerr DJ; Searle PF
Gene Ther; 1998 Aug; 5(8):1061-9. PubMed ID: 10326029
[TBL] [Abstract][Full Text] [Related]
32. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
33. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
Hu L; Wu X; Han J; Chen L; Vass SO; Browne P; Hall BS; Bot C; Gobalakrishnapillai V; Searle PF; Knox RJ; Wilkinson SR
Bioorg Med Chem Lett; 2011 Jul; 21(13):3986-91. PubMed ID: 21620697
[TBL] [Abstract][Full Text] [Related]
35. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation.
Emptage CD; Knox RJ; Danson MJ; Hough DW
Biochem Pharmacol; 2009 Jan; 77(1):21-9. PubMed ID: 18840409
[TBL] [Abstract][Full Text] [Related]
36. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
[TBL] [Abstract][Full Text] [Related]
37. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
38. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.
Knox RJ; Friedlos F; Sherwood RF; Melton RG; Anlezark GM
Biochem Pharmacol; 1992 Dec; 44(12):2297-301. PubMed ID: 1472095
[TBL] [Abstract][Full Text] [Related]
39. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
[TBL] [Abstract][Full Text] [Related]
40. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
